Zynlonta™(loncastuximab tesirine-lpyl) – New drug approval
On April 23, 2021 - ADC Therapeutics announced the FDA approval of Zynlonta (loncastuximab tesirine-lpyl), for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma
Top